• Saturday, Dec 14, 2019
  • Last Update : 11:51 am

DGDA suspends production, distribution, sale, export of ranitidine

  • Published at 04:50 pm November 14th, 2019
web-drug-medicine
Representational photo: Bigstock

Bangladesh drug authority has previously imposed a temporary ban on ranitidine tablets on September 29

The Directorate General of Drug Administration (DGDA) has suspended production, distribution, sale and export of drug ranitidine following detection of cancer causing ingredients in its raw materials.

DGDA made the announcement through a public notice on Wednesday.

The sample of ranitidine’s raw ingredients, supplied by Indian companies Saraka Laboratories Ltd and SMS Life Science, and its finished products were sent to the World Health Organization (WHO) accredited laboratories to run tests.

The test result shows existence of cancer causing ingredient N-nitrosodimethylamine (NDMA) in the ingredients.

On September 29, the drug authority in Bangladesh imposed a temporary ban on the import, production, and sale of ranitidine tablets.

The decision came after GlaxoSmithKline Pharmaceuticals’ voluntary recall of ranitidine tablets produced in India following an alleged detection of genotoxic nitrosamine NDMA by global, and Indian regulatory authorities.

Ranitidine tablets are mostly used to treat ulcers of the stomach.